169 related articles for article (PubMed ID: 36971495)
1. HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population.
Zhou L; Shao Z; Liu Y; Yan X; Li J; Wu X; Tang B; Li S; Cui C; Chi Z; Si L; Kong Y; Mao L; Lian B; Wang X; Bai X; Dai J; Guo J; Sheng X
Oncologist; 2023 Aug; 28(8):e617-e624. PubMed ID: 36971495
[TBL] [Abstract][Full Text] [Related]
2. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.
Zhu K; Chang Y; Zhao D; Guo A; Cao J; Wu C; Guan Y; Ding S
Front Pharmacol; 2024; 15():1355081. PubMed ID: 38455962
[No Abstract] [Full Text] [Related]
3. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
4. High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder.
Lee YE; Chan TC; Tian YF; Liang PI; Shiue YL; Chen YS; He HL
Urol Oncol; 2019 May; 37(5):299.e7-299.e18. PubMed ID: 30660494
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Analysis of HER2, EGFR, and Nectin-4 Expression in Upper Urinary Tract Urothelial Carcinoma.
Hashimoto M; Fujita K; Tomiyama E; Fujimoto S; Adomi S; Banno E; Minami T; Takao T; Nozawa M; Fushimi H; Yoshimura K; Nonomura N; Uemura H
Anticancer Res; 2023 Jan; 43(1):167-174. PubMed ID: 36585180
[TBL] [Abstract][Full Text] [Related]
6. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.
Wei Y; Zhang R; Yu C; Hong Z; Lin L; Li T; Chen J
Front Pharmacol; 2023; 14():1230395. PubMed ID: 37645442
[No Abstract] [Full Text] [Related]
7. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
Schneider SA; Sukov WR; Frank I; Boorjian SA; Costello BA; Tarrell RF; Thapa P; Houston Thompson R; Tollefson MK; Jeffrey Karnes R; Cheville JC
Mod Pathol; 2014 May; 27(5):758-64. PubMed ID: 24186136
[TBL] [Abstract][Full Text] [Related]
9. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF
J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739
[TBL] [Abstract][Full Text] [Related]
10. FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.
Fan EW; Li CC; Wu WJ; Huang CN; Li WM; Ke HL; Yeh HC; Wu TF; Liang PI; Ma LJ; Li CF
J Urol; 2015 Jul; 194(1):223-9. PubMed ID: 25623741
[TBL] [Abstract][Full Text] [Related]
11. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
12. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).
Soria F; Moschini M; Haitel A; Wirth GJ; Karam JA; Wood CG; Rouprêt M; Margulis V; Karakiewicz PI; Briganti A; Raman JD; Kammerer-Jacquet SF; Mathieu R; Bensalah K; Lotan Y; Özsoy M; Remzi M; Gust KM; Shariat SF
World J Urol; 2017 Feb; 35(2):251-259. PubMed ID: 27272502
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single‑center experience.
Bai X; He W; Yin H; Li X; Zhou X; Wei Z; Yu H; Gou X
Exp Ther Med; 2022 Nov; 24(5):704. PubMed ID: 36324611
[TBL] [Abstract][Full Text] [Related]
14. Genomic Characterization of Upper Tract Urothelial Carcinoma.
Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
[TBL] [Abstract][Full Text] [Related]
15. Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival.
Li G; Yu J; Song H; Zhu S; Sun L; Shang Z; Niu Y
BMC Cancer; 2017 Aug; 17(1):530. PubMed ID: 28789622
[TBL] [Abstract][Full Text] [Related]
16. HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder.
Kim B; Kim G; Song B; Lee C; Park JH; Moon KC
Dis Markers; 2016; 2016():8463731. PubMed ID: 27034533
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
D'Andrea D; Matin S; Black PC; Petros FG; Zargar H; Dinney CP; Cookson MS; Kassouf W; Dall'Era MA; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; Sridhar SS; North S; Barocas DA; Lotan Y; Stephenson AJ; van Rhijn BW; Spiess PE; Daneshmand S; Shariat SF
BJU Int; 2021 May; 127(5):528-537. PubMed ID: 32981193
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques.
Nedjadi T; Al-Maghrabi J; Assidi M; Dallol A; Al-Kattabi H; Chaudhary A; Al-Sayyad A; Al-Ammari A; Abuzenadah A; Buhmeida A; Al-Qahtani M
BMC Cancer; 2016 Aug; 16():653. PubMed ID: 27539085
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
Liang PI; Lai HY; Chan TC; Li WM; Hsing CH; Huang SK; Hsieh KL; Tseng WH; Chen TJ; Li WS; Chen HD; Kuo YH; Li CF
BMC Cancer; 2023 Jun; 23(1):599. PubMed ID: 37380971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
